FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996629241> ?p ?o ?g. }

• W1996629241 endingPage "1541" @default.
• W1996629241 startingPage "1534" @default.
• W1996629241 abstract "Statins and fibrates have different effects on lipid abnormalities of familial combined hyperlipidemia (FCHL); thus, the selection of the first-line drug is troublesome. We evaluated to what extent monotherapy with a potent statin is more effective than fibrate in reaching the recommended lipid targets in FCHL. Fifty-six patients were randomized to receive optimal dosage of atorvastatin (n = 27) or 200 mg/d micronized fenofibrate (n = 29) for 24 weeks. To reach the optimal dosage, atorvastatin was up-titrated at each follow-up visit if low-density lipoprotein (LDL) cholesterol >130 mg/dL (>100 mg/dL in patients with coronary or cerebrovascular disease). The effects of fenofibrate and atorvastatin on lipoprotein fractions as well as on plasma levels of endothelin-1 (ET-1) and adrenomedullin (AM) were also evaluated. At end of trial, a greater proportion of patients on atorvastatin (average dosage, 20.8 mg/d) reached lipid targets in comparison with those on fenofibrate (64% vs 32.1%, P = .02). Atorvastatin was significantly more effective in reducing total cholesterol, LDL cholesterol, apolipoprotein B, and non–high-density lipoprotein (HDL) cholesterol. Conversely, triglycerides decreased and HDL increased more during fenofibrate. Nevertheless, atorvastatin produced a marked reduction in very low-density lipoprotein and very low-density lipoprotein remnants. Atorvastatin lowered all LDL subtypes, although fenofibrate appeared to be more effective on denser LDL. Compared with 43 normolipemic controls, FCHL patients presented increased baseline plasma levels of ET-1 (P = .007) but not of AM. Fenofibrate, but not atorvastatin, significantly lowered ET-1 levels by 16.7% (P < .05). Neither drug significantly affected plasma concentrations of AM. In summary, although fenofibrate showed superiority in raising HDL and reducing ET-1, atorvastatin was more effective in reaching lipid targets in FCHL so that it can be proposed as the first-line option in the management of this atherogenic hyperlipidemia." @default.
• W1996629241 created "2016-06-24" @default.
• W1996629241 creator A5004045400 @default.
• W1996629241 creator A5014381368 @default.
• W1996629241 creator A5023770804 @default.
• W1996629241 creator A5024394361 @default.
• W1996629241 creator A5041056118 @default.
• W1996629241 creator A5052983016 @default.
• W1996629241 creator A5076544363 @default.
• W1996629241 creator A5077173779 @default.
• W1996629241 creator A5086949920 @default.
• W1996629241 creator A5090692982 @default.
• W1996629241 date "2007-11-01" @default.
• W1996629241 modified "2023-10-13" @default.
• W1996629241 title "Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia" @default.
• W1996629241 cites W1533245272 @default.
• W1996629241 cites W1775749144 @default.
• W1996629241 cites W1969927159 @default.
• W1996629241 cites W1970827324 @default.
• W1996629241 cites W1989905775 @default.
• W1996629241 cites W1994096411 @default.
• W1996629241 cites W1997488980 @default.
• W1996629241 cites W2014237668 @default.
• W1996629241 cites W2017296120 @default.
• W1996629241 cites W2028401356 @default.
• W1996629241 cites W2029561034 @default.
• W1996629241 cites W2048220093 @default.
• W1996629241 cites W2050939945 @default.
• W1996629241 cites W2054851194 @default.
• W1996629241 cites W2072793621 @default.
• W1996629241 cites W2073885314 @default.
• W1996629241 cites W2077338443 @default.
• W1996629241 cites W2088367417 @default.
• W1996629241 cites W2093987460 @default.
• W1996629241 cites W2097754892 @default.
• W1996629241 cites W2116223905 @default.
• W1996629241 cites W2116719149 @default.
• W1996629241 cites W2130576404 @default.
• W1996629241 cites W2132827941 @default.
• W1996629241 cites W2138156113 @default.
• W1996629241 cites W2138599787 @default.
• W1996629241 cites W2140515829 @default.
• W1996629241 cites W2142802148 @default.
• W1996629241 cites W2146262274 @default.
• W1996629241 cites W2148459936 @default.
• W1996629241 cites W2152211449 @default.
• W1996629241 cites W2152390702 @default.
• W1996629241 cites W2154704322 @default.
• W1996629241 cites W2155097495 @default.
• W1996629241 cites W2160595143 @default.
• W1996629241 cites W2163437618 @default.
• W1996629241 cites W2164941554 @default.
• W1996629241 cites W2317393176 @default.
• W1996629241 cites W4238251256 @default.
• W1996629241 doi "https://doi.org/10.1016/j.metabol.2007.06.021" @default.
• W1996629241 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17950105" @default.
• W1996629241 hasPublicationYear "2007" @default.
• W1996629241 type Work @default.
• W1996629241 sameAs 1996629241 @default.
• W1996629241 citedByCount "19" @default.
• W1996629241 countsByYear W19966292412012 @default.
• W1996629241 countsByYear W19966292412013 @default.
• W1996629241 countsByYear W19966292412015 @default.
• W1996629241 countsByYear W19966292412018 @default.
• W1996629241 countsByYear W19966292412019 @default.
• W1996629241 countsByYear W19966292412020 @default.
• W1996629241 countsByYear W19966292412022 @default.
• W1996629241 countsByYear W19966292412023 @default.
• W1996629241 crossrefType "journal-article" @default.
• W1996629241 hasAuthorship W1996629241A5004045400 @default.
• W1996629241 hasAuthorship W1996629241A5014381368 @default.
• W1996629241 hasAuthorship W1996629241A5023770804 @default.
• W1996629241 hasAuthorship W1996629241A5024394361 @default.
• W1996629241 hasAuthorship W1996629241A5041056118 @default.
• W1996629241 hasAuthorship W1996629241A5052983016 @default.
• W1996629241 hasAuthorship W1996629241A5076544363 @default.
• W1996629241 hasAuthorship W1996629241A5077173779 @default.
• W1996629241 hasAuthorship W1996629241A5086949920 @default.
• W1996629241 hasAuthorship W1996629241A5090692982 @default.
• W1996629241 hasConcept C126322002 @default.
• W1996629241 hasConcept C134018914 @default.
• W1996629241 hasConcept C185592680 @default.
• W1996629241 hasConcept C2776839432 @default.
• W1996629241 hasConcept C2776933373 @default.
• W1996629241 hasConcept C2777482532 @default.
• W1996629241 hasConcept C2778110834 @default.
• W1996629241 hasConcept C2778163477 @default.
• W1996629241 hasConcept C2778913445 @default.
• W1996629241 hasConcept C2779091943 @default.
• W1996629241 hasConcept C2780072125 @default.
• W1996629241 hasConcept C555293320 @default.
• W1996629241 hasConcept C62746215 @default.
• W1996629241 hasConcept C71924100 @default.
• W1996629241 hasConcept C98274493 @default.
• W1996629241 hasConceptScore W1996629241C126322002 @default.
• W1996629241 hasConceptScore W1996629241C134018914 @default.
• W1996629241 hasConceptScore W1996629241C185592680 @default.
• W1996629241 hasConceptScore W1996629241C2776839432 @default.

• next